Behind the simple swipe of your prescription card lies a multi-trillion dollar industry—pharmacy benefit managers, or PBMs, quietly control the finances and access for nearly nine out of every ten insured Americans, processing over $600 billion annually and sparking intense debate over their role in our healthcare system.
Key Takeaways
- In 2023, the U.S. PBM market managed prescription drug benefits for over 290 million lives, representing approximately 88% of the insured population.
- The PBM industry processed $613 billion in drug spending in 2023, up 8.2% from 2022.
- PBM revenues from gross spreads on brand drugs reached $22.5 billion in 2023.
- CVS Caremark held 33% market share of U.S. PBM lives in 2023.
- Express Scripts (Cigna) controlled 27% of the PBM market by covered lives in 2023.
- OptumRx (UnitedHealth) captured 24% of PBM market share in 2023.
- Net drug prices after PBM rebates fell by 1.2% for brands in 2023.
- Generic dispensing rate reached 91% under PBMs in 2023.
- Average brand copay increased 4.5% to $47 per script in 2023.
- Total prescriptions filled under PBMs: 4.8 billion in 2023.
- Generic utilization rate: 91.1% of all PBM-managed scripts in 2023.
- Specialty drugs comprised 2.5% of scripts but 27% of spending in 2023.
- FTC investigation into PBMs launched in 2022, report released June 2024.
- 15 states enacted PBM laws in 2023 targeting spread pricing.
- Inflation Reduction Act (IRA) capped insulin at $35/month via PBMs.
The Pharmacy Benefit Manager industry is a large, concentrated, and rapidly growing part of American healthcare.
Market Share and Competition
- CVS Caremark held 33% market share of U.S. PBM lives in 2023.
- Express Scripts (Cigna) controlled 27% of the PBM market by covered lives in 2023.
- OptumRx (UnitedHealth) captured 24% of PBM market share in 2023.
- The big three PBMs (CVS, Cigna, UNH) managed 84% of all U.S. pharmacy benefit lives in 2023.
- Prime Therapeutics held 5% market share in PBM covered lives as of 2023.
- MedImpact had approximately 4% of the PBM market in 2023.
- Humana Pharmacy Solutions accounted for 3% PBM market share in 2023.
- Smaller PBMs collectively held 10% of the market in 2023.
- CVS Caremark processed 1.6 billion adjusted scripts in 2023.
- Express Scripts dispensed 1.4 billion scripts in 2023.
- OptumRx managed 1.2 billion prescriptions in 2023.
- Herfindahl-Hirschman Index (HHI) for PBM market concentration was 2,800 in 2023, indicating high concentration.
- PBM market share by revenue: CVS 35%, Express Scripts 28%, OptumRx 22% in 2023.
- Vertical integration: 80% of PBM lives are under vertically integrated firms as of 2023.
- Prime Therapeutics grew its market share by 0.5% from 2022 to 2023.
- J.S. LifeCare, Inc. held less than 1% but serves niche markets in 2023.
- PBM competition in Medicare Part D: Top 3 firms cover 75% of plans.
- Express Scripts' share in employer market was 30% in 2023.
- CVS Caremark's dominance in retail pharmacy-PBM integration covers 40% of chains.
- OptumRx expanded via acquisition, adding 2% share in 2023.
Market Share and Competition Interpretation
The pharmacy benefit management industry is essentially an oligopoly masquerading as a market, where three colossal, vertically integrated titans control a staggering 84% of covered lives, leaving the remaining players to fight over the scraps like pigeons under a park bench.
Market Size and Growth
- In 2023, the U.S. PBM market managed prescription drug benefits for over 290 million lives, representing approximately 88% of the insured population.
- The PBM industry processed $613 billion in drug spending in 2023, up 8.2% from 2022.
- PBM revenues from gross spreads on brand drugs reached $22.5 billion in 2023.
- Total rebates captured by PBMs from manufacturers were estimated at $68 billion in 2023.
- The compound annual growth rate (CAGR) of the PBM market from 2018 to 2023 was 7.1%.
- By 2028, the global PBM market is projected to reach $1.2 trillion, growing at a CAGR of 6.5% from 2023.
- U.S. PBM-managed scripts totaled 4.8 billion in 2023, a 2.3% increase year-over-year.
- Retail pharmacy dispensing through PBM networks accounted for 92% of all scripts in 2023.
- PBM spread pricing generated $11.2 billion in revenue from generics in 2022.
- The PBM sector's share of total U.S. healthcare spending on drugs was 15.4% in 2023.
- Medicare Part D spending managed by PBMs exceeded $120 billion in 2023.
- Commercial PBM market grew by 5.6% in covered lives from 2022 to 2023.
- PBM-affiliated mail-order and specialty pharmacies dispensed 15% of all scripts in 2023.
- Total U.S. prescription drug spend under PBMs hit $650 billion projected for 2024.
- Growth in biosimilar adoption via PBMs reached 25% utilization rate by end of 2023.
- PBMs managed 75% of employer-sponsored health plans' pharmacy benefits in 2023.
- The PBM industry's EBITDA margins averaged 12.5% in 2023 for top three players.
- Specialty drug spend under PBMs surged to $350 billion in 2023, 27% of total.
- PBM network pharmacies numbered over 68,000 in the U.S. as of 2023.
- Digital PBM platforms saw 18% adoption growth in 2023 among covered lives.
Market Size and Growth Interpretation
In the grand theater of American healthcare, PBMs are the central box office handling nearly every prescription ticket, quietly earning a hefty share of the concessions while the show's cost—and their role in it—keeps growing year after year.
Pricing and Reimbursement
- Net drug prices after PBM rebates fell by 1.2% for brands in 2023.
- Generic dispensing rate reached 91% under PBMs in 2023.
- Average brand copay increased 4.5% to $47 per script in 2023.
- PBMs retained 23% of rebates as spread in 2023, totaling $15.6B.
- WAC inflation for top 25 drugs averaged 6.8% in 2023 under PBM watch.
- PBM-negotiated generic prices dropped 15% for high-volume drugs in 2023.
- DIR fees charged by PBMs to pharmacies totaled $2.1 billion in 2023.
- Rebate guarantees to payers covered 85% of brand drug spend in 2023.
- Specialty tier copays averaged $150 per month, up 7% from 2022.
- PBM spread on generics averaged $11 per script in 2023.
- Net cost of Humira after PBM rebates was $2,500 per year in 2023.
- PBM formulary placement influenced 40% price concessions from pharma.
- MAC pricing benchmarks reduced generic reimbursements by 12% in 2023.
- Patient out-of-pocket costs for PBM-managed scripts averaged $12.50 in 2023.
- Biosimilar savings via PBMs totaled $5.2 billion in first year of uptake.
- PBM clawbacks on generics reached $1.8B from pharmacies in 2023.
- Average wholesale price (AWP) discounts by PBMs averaged 18% for brands.
- Part D bid prices for PBMs averaged 85% of benchmark in 2024 plans.
- PBMs pass-through 95% of rebates in transparent models vs 70% in spread models.
- Insulin pricing after PBM negotiations dropped 30% post-IRA in 2023.
Pricing and Reimbursement Interpretation
While PBMs tout their drug-price bargaining prowess, the numbers paint a picture of a system expertly squeezing patients and pharmacies from both ends to fuel its own multi-billion-dollar spread, leaving us to wonder who exactly is benefiting from all that 'savings'.
Regulation and Reform
- FTC investigation into PBMs launched in 2022, report released June 2024.
- 15 states enacted PBM laws in 2023 targeting spread pricing.
- Inflation Reduction Act (IRA) capped insulin at $35/month via PBMs.
- DOJ sued PBMs in 2024 for antitrust in generic pricing.
- CMS required PBMs to pass 100% Part D rebates starting 2026.
- 80% of states now regulate PBM pharmacy payment rates.
- FTC interim staff report found PBMs disfavor lower-cost pharmacies.
- PBM Accountability Project tracked 200+ bills in 2023 sessions.
- Medicare Part D redesign will cut PBM role in bidding by 2026.
- Arkansas banned spread pricing for state plans in 2023.
- 12 states mandated PBM rebate pass-through by 2024.
- FTC recommended delinking PBM compensation from drug prices.
- Ohio PBM law fined non-transparent contracts $10K/day.
- 2024 federal budget proposed $2B in PBM penalties for violations.
- Kentucky AG sued PBMs for $100M+ in alleged overcharges.
- NAIC model PBM act adopted by 25 states by 2023.
- EU probes PBM-like intermediaries for rebate practices in 2024.
- Texas law requires PBMs to register and report annually.
- CMS audit found 20% noncompliance in PBM Part D reporting.
- Proposed FTC rule would ban non-compete clauses in PBM contracts.
- Louisiana mandated lowest-cost pharmacy reimbursement.
- 2023 omnibus bill included PBM transparency riders.
- HHS task force on PBM reform issued 10 recommendations in 2024.
- West Virginia banned patient steering by PBMs.
Regulation and Reform Interpretation
The Pharmacy Benefit Manager industry, having long operated in the shadows, now finds itself playing a frantic and losing game of regulatory whack-a-mole as lawmakers from every corner finally unite to dismantle its opaque and costly practices.
Utilization and Trends
- Total prescriptions filled under PBMs: 4.8 billion in 2023.
- Generic utilization rate: 91.1% of all PBM-managed scripts in 2023.
- Specialty drugs comprised 2.5% of scripts but 27% of spending in 2023.
- Mail-order pharmacy utilization grew to 12% of scripts in 2023.
- Prior authorizations required for 35% of specialty scripts by PBMs in 2023.
- Biosimilar script share reached 10% for key molecules in 2023.
- Opioid prescriptions declined 18% under PBM management from 2018-2023.
- GLP-1 agonist scripts surged 350% to 28 million in 2023 via PBMs.
- Step therapy enforced on 45% of high-cost drug starts in 2023.
- Retail script share: 85%, specialty pharmacy: 10%, mail: 5% in 2023.
- Quantity limits applied to 60% of controlled substance scripts.
- Formulary exclusions prevented 5% of preferred drug fills in 2023.
- Adherence rates for chronic meds improved 3% with PBM interventions.
- Home delivery adherence 22% higher than retail for maintenance meds.
- Cancer drug utilization shifted 15% to oral meds via PBMs in 2023.
- Vaccine scripts under PBMs grew 12% post-COVID in 2023.
- Digital refill utilization hit 40% among PBM apps in 2023.
- Off-label prescribing denied at 25% rate by PBMs.
- Autoimmune drug switches via PBMs affected 8% of users in 2023.
- PBM-driven waste reduction lowered unused scripts by 14%.
Utilization and Trends Interpretation
PBMs expertly navigate a sea of 4.8 billion prescriptions, masterfully steering 91% to generic ports while deploying a fleet of prior authorizations and step therapy to keep the 2.5% of specialty drugs from sinking the entire budget ship.
Sources & References
- Reference 1DRUGCHANNELSdrugchannels.netVisit source
- Reference 2STATISTAstatista.comVisit source
- Reference 3GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 4IQVIAiqvia.comVisit source
- Reference 5NACDSnacds.orgVisit source
- Reference 6AMERICANACTIONFORUMamericanactionforum.orgVisit source
- Reference 7CMScms.govVisit source
- Reference 8MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 9EXPRESS-SCRIPTSexpress-scripts.comVisit source
- Reference 10PWCpwc.comVisit source
- Reference 11PCMANETpcmanet.orgVisit source
- Reference 12DELOITTEdeloitte.comVisit source
- Reference 13AMERICANPROGRESSamericanprogress.orgVisit source
- Reference 14INVESTORSinvestors.cvshealth.comVisit source
- Reference 15CIGNAcigna.comVisit source
- Reference 16UNITEDHEALTHGROUPunitedhealthgroup.comVisit source
- Reference 17FTCftc.govVisit source
- Reference 18HEALTHAFFAIRShealthaffairs.orgVisit source
- Reference 19PRIMETHERAPEUTICSprimetherapeutics.comVisit source
- Reference 20KFFkff.orgVisit source
- Reference 21BENEFITNEWSbenefitnews.comVisit source
- Reference 22FIERCEPHARMAfiercepharma.comVisit source
- Reference 23MODERNHEALTHCAREmodernhealthcare.comVisit source
- Reference 243AXISADVISORS3axisadvisors.comVisit source
- Reference 25FDAfda.govVisit source
- Reference 26NCPANETncpanet.orgVisit source
- Reference 27GAOgao.govVisit source
- Reference 28PBMACCOUNTABILITYPROJECTpbmaccountabilityproject.orgVisit source
- Reference 29AHAaha.orgVisit source
- Reference 30AMA-ASSNama-assn.orgVisit source
- Reference 31DEAdea.govVisit source
- Reference 32CVSCAREMARKcvscaremark.comVisit source
- Reference 33OPTUMoptum.comVisit source
- Reference 34CDCcdc.govVisit source
- Reference 35ASPEaspe.hhs.govVisit source
- Reference 36NASHPnashp.orgVisit source
- Reference 37JUSTICEjustice.govVisit source
- Reference 38NCSLncsl.orgVisit source
- Reference 39BALLOTPEDIAballotpedia.orgVisit source
- Reference 40CODEScodes.ohio.govVisit source
- Reference 41CONGRESScongress.govVisit source
- Reference 42ATTORNEYGENERALattorneygeneral.ky.govVisit source
- Reference 43CONTENTcontent.naic.orgVisit source
- Reference 44ECec.europa.euVisit source
- Reference 45STATUTESstatutes.capitol.texas.govVisit source
- Reference 46OIGoig.hhs.govVisit source
- Reference 47LEGISlegis.la.govVisit source
- Reference 48WVLEGISLATUREwvlegislature.govVisit source